Instructions for Authors 2018

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tif or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**Nomenclature and Abbreviations.** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (http://www.gene.ucl.ac.uk/). Approved mouse nomenclature may be obtained from http://www.informatics.jax.org/. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trial number should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXX (where XXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXX (where XXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

**Ethical Policies and Standards.** ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”.

Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html

In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

**Specific information and additional instructions for Authors**

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.

2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
   - The Instructions to Authors must be followed in every detail.
   - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
   - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
   - Results given in figures should not be repeated in tables.
   - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
   - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
   - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
   - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
   - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
   - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
   - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

9. Articles submitted to AR may be rejected without review if:
   - they do not fall within the journal's policy.
   - they do not follow the instructions for authors.
   - language is unclear.
   - results are not sufficient to support a final conclusion.
   - results are not objectively based on valid experiments.
   - they repeat results already published by the same or other authors before the submission to AR.
   - plagiarism is detected by plagiarism screening services.
   (Rejection rate (2016): 66%).

10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org

12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.
   (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2018 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
General Policy

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research.

The principal aim of IN VIVO is to provide prompt open line publication for accepted articles, generally within 1-2 months from final acceptance.

Editorial Office: International Institute of Anticancer Research, 1st km Panadriou-Kalamou Rd., P.O. Box 22, Panadri, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIA R WEBSITES: www.iiar-anticancer.org and www.iiarjournals.org

International Journal of Experimental and Clinical Pathophysiology and Drug Research

Published bimonthly by the International Institute of Anticancer Research

Available online only and open access with Stanford University HighWire Press

Selection of Recent Articles


Morphological Distinction of Histiocytic Sarcoma from Other Tumor Types in Bernese Mountain Dogs and Flatcoated Retrievers. S.A. ERICH, F. CONSTANTINO-CASAS, J.M. DOBSON, E. TESKE (Utrecht, The Netherlands; Cambridge, UK)


Clinical Impact of Rest Dual-Energy Computed Tomography Myocardial Perfusion in Patients with Coronary Artery Disease. S. BAUMANN, et al. (Mannheim, Germany)


Profiling Neutrophil-to-Lymphocyte Ratio Changes in Response to Nucleoside Analog Therapy for Chronic Hepatitis B Infection. M. MARALLAG, A. PATEL, M. CHOI, M.N. WONG, A.B. SEETHARAM (Phoenix; Tempe, AZ, USA)

Comparison of the Grip Strength Using the Martin-Vigorimeter and the JAMAR-Dynamometer: Establishment of Normal Values. S. NEUMANN, S. KWISDA, C. KRETTEK, R. GAULKE (Hannover; Hamburg, Germany; Zurich, Switzerland)

Role for Neutrophil Extracellular Traps (NETs) and Platelet Aggregation in Early Sepsis-induced Hepatic Dysfunction. K. SAKURAI, T. MIYASHITA, et al. (Ishikawa, Japan; Baltimore, MD, USA)

Netrin-4 Promotes Differentiation and Migration of Osteoblasts. Y. ENOKI, T. SATO, S. KOKUBU, N. HAYASHI, T. IWATA, M. YAMATO, M. USUI, M. MATSUMOTO, T. TOMODA, W. ARIYOSHI, T. NISHIHARA, T. YODA (Saitama; Fukuoka; Tokyo, Japan)

Early PET-CT After Stereotactic Radiotherapy for Stage I Non-small-cell Lung Carcinoma Is Predictive of Local Control. M. TYRAN, N. CHARRIER, J. DARREON, A. MADROSZYK, A. TALLET, N. SALEM (Marseille, France)

Tumor Hypoxia Detected by $^{18}$F-fluoromisonidazole Positron Emission Tomography (FMISO PET) as a Prognostic Indicator of Radiotherapy (RT). I. TACHIBANA, Y. NISHIMURA, K. HANAOKA, M. INADA, K. FUKUDA, H. TATEBE, K. ISHIKAWA, K. NAKAMATSU, S. KANAMORI, M. HOSONO (Osakasayama, Japan) .................................................................


Defunctioning Ileostomy Is a Key Risk Factor for Small Bowel Obstruction After Colorectal Cancer Resection. K. ETO, M. KOSUGE, M. OHKUMA, R. NOAKI, K. NEKI, D. ITO, H. SUGANO, Y. TAKEDA, K. YANAGA (Tokyo, Japan) ..................................................................................................................................


Outcome of Trimodal Therapy in Elderly Patients with Esophageal Cancer: Prognostic Value of the Charlson Comorbidity Index. D. BERNARDI, E. ASTI, A. AIOLFI, G. BONITTA, A. LUPORINI, L. BONAVINA (Milan, Italy) ............................................................................................................................................................

High Frequency of Spread Through Air Spaces in Resected Small Cell Lung Cancer. G. TOYOKAWA, Y. YAMADA, T. TAGAWA, F. KINOSHITA, Y. KOZUMA, T. MATSUBARA, N. HARATAKE, S. TAKAMORI, T. AKAMINE, F. HIRAI, Y. ODA, Y. MAEHARA (Fukuoka, Japan) .................................................................

ABSTRACTS OF THE 5TH INTERNATIONAL CONFERENCE ON ADVANCES IN HEMATOLOGY AND ONCOLOGY (ICAHO2017) 12-13 August, 2017 (Coeur d’Alene, ID, USA) .................................................................
Evaluation of Optimal Lymph Node Dissection in Remnant Gastric Cancer Based on Initial Distal Gastrectomy. K. IGUCHI, C. KUNISAKI, S. SATO, Y. TANAKA, H. MIYAMOTO, T. KOSAKA, H. AKIYAMA, I. ENDO, Y. RINO, M. MASUDA (Yokohama, Japan) ................................................................. 1677

Prognostic Significance of High EphA1-4 Expression Levels in Locally Advanced Gastric Cancer. M. INOKUCHI, M. NAKAGAWA, N. BAOGOK, Y. TAKAGI, T. TANIOKA, K. GOKITA, K. OKUNO, K. KOJIMA (Tokyo, Japan) .................................................................................................................. 1685

Rates, Sites and Times of Recurrence and Clinical Outcome of Endometrial Cancer Patients with Histologically-positive Nodes: An Italian Two-center Retrospective Study. A. GADDUCCI, M.E. GUERRIERI, S. COSIO, M.G. FABRINI, C. LALISCIA, D. ATTIANESE, A. ROSSI, A. FERRERO (Pisa; Turin, Italy) .................................................................................................................................................. 1695

Contribution of Patient-reported Symptoms Before Palliative Radiotherapy to Development of Multivariable Prognostic Models. C. NIEDER, T.A. KÄMPE (Bodø; Tromsø, Norway) .................................................................................................................. 1705

Case Report: CEA Elevation Can Be a Marker of Increased Inflammation During Treatment with Oxaliplatin. D. KERR, D. LABER, N. VISWESHWAR, M. JAGLAL (Tampa, FL, USA) .................................................................................................................. 1711

Safety of Simultaneous Bilateral Pulmonary Resection for Metastatic Lung Tumors. T. MATSUBARA, G. TOYOKAWA, F. KINOSHITA, N. HARATAKE, Y. KOZUMA, T. AKAMORI, F. HIRAI, T. TAGAWA, T. OKAMOTO, Y. MAEHARA (Fukuoka, Japan) ................................................................. 1715

Laparoscopy-assisted Distal Gastrectomy for Gastric Cancer in Elderly Patients: Surgical Outcomes and Prognosis. K. ARATANI, S. SAKURAMOTO, M. CHUMAN, M. KASUYA, M. WAKATA, Y. MIYAWAKI, H. GUNJI, H. SATO, K. OKAMOTO, S. YAMAGUCHI, E. OTSUJI, I. KOYAMA (Hidaka; Kyoto, Japan) ................................................................. 1721


Ki-67 and Survivin as Predictive Factors for Rectal Cancer Treated with Preoperative Chemoradiotherapy. K. YOSHIKAWA, M. SHIMADA, J. HIGASHIJIMA, T. NAKAO, M. NISHI, C. TAKASU, H. KASHIHARA, S. ETO, Y. BANDO (Tokushima, Japan) ................................................................. 1735


The Modified Glasgow Prognostic Score in Patients with Gemcitabine-refractory Biliary Tract Cancer. N. OKANO, A. KASUGA, K. KAWAI, Y. YAMAUCHI, T. KOBAYASHI, D. NARUGE, F. NAGASHIMA, J. FURUSE (Tokyo, Japan) .................................................................................................................. 1755

Preoperative Staging of Pelvic Lymph Nodes in Prostate Cancer Patients via Endorectal Magnetic Resonance Imaging. V. ZUGOR, M. VON BRANDENSTEIN, I. AKBAROV, D. PORRES, R. KÜHN, A.P. LABANARIS (Cologne; Nuremberg, Germany; Thessaloniki, Greece) .................................................................................................................. 1763

Clinicopathological Characteristics of High-grade Squamous Intraepithelial Lesions Involving Condyloma Acuminatum. K. NA, J.-Y. SUNG, H.-S. KIM (Seoul, Republic of Korea) .................................................................................................................. 1767

Contents continued on the preceding page


A New Scoring-system for Estimating Overall Survival After Radiotherapy of Recurrent Head and Neck Cancers. D. RADES, D. SEIDL, S. JANSSEN, S.G. HAKIM, B. WOLLENBERG, T. BARTSCHT, S.E. SCHILD (Lübeck; Hannover, Germany; Scottsdale, AZ, USA) .................................................................................................................. 1611


mTORC1 and mTORC2 Expression Levels in Oral Squamous Cell Carcinoma: An Immunohistochemical and Clinicopathological Study. G. KAWASAKI, T. NARUSE, K. FURUKAWA, M. UMEDA (Nagasaki, Japan) .......................................................................................................................... 1623

Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy. Y. MIYATA, T. MATSUO, Y. NAKAMURA, T. YASUDA, K. OHBA, K. TAKEHARA, H. SAKAI (Nagasaki, Japan) .................................................................................................................. 1629

Associations Between Histogram Analysis DCE MRI Parameters and Complex \(^{18}\)F-FDG-PET Values in Head and Neck Squamous Cell Carcinoma. A. SUROV, L. LEIFELS, H.J. MEYER, K. WINTER, O. SABRI, S. PURZ (Leipzig, Germany) .................................................................................................................. 1637

Lenvatinib in Advanced Radioiodine-refractory Thyroid Cancer: A Snapshot of Real-life Clinical Practice. A. NERVO, M. GALLO, M.T. SAMÁ, F. FELICETTI, M. ALFANO, E. MIGLIORE, F. MARCHISIO, R. BERARDELLI, E. ARVAT, A. PIOVESAN (Turin, Italy) .................................................................................................................. 1643

National Practice Patterns for Clinical T1N0 Nasopharyngeal Cancer in the Elderly: A National Cancer Data Base Analysis. C.M. POST, C. LIN, S. ADEBERG, M. GUPTA, W. ZHEN, V. VERMA (Omaha, NE; Kansas City, MO; Heidelberg, Germany) .................................................................................................................. 1651

Upper Abdominal Resection for Isolated Metastatic Lesions in Recurrent Cervical Cancer. A. FILIPESCU, I. BALESCU, N. BACALBASA (Bucharest, Romania) .................................................................................................................. 1659

A Retrospective Multicenter Study of Carbon Ion Radiotherapy for Locally Advanced Olfactory Neuroblastomas. H. SUEFUJI, M. KOTO, Y. DEMIZU, J.-I. SAITO, Y. SHIOYAMA, H. TSUI, T. OKIMOTO, T. OHNO, K. NEMOTO, T. NAKANO, T. KAMADA (Tosu; Chiba; Tatsuno; Maebashi; Yamagata, Japan) .................................................................................................................. 1665


Contents continued on the preceding page

Serum C-reactive Protein and Neutrophil/Lymphocyte Ratio After Neoadjuvant Radiotherapy in Soft Tissue Sarcoma. M. YANAGISAWA, A.A. GINGRICH, S. JUDGE, C.-S. LI, N. WANG, S.W. THORPE, A.R. KIRANE, R.J. BOLD, A.M. MONJAZEB, R.J. CANTER (Sacramento; Davis, CA, USA) ............................ 1491


Surveillance Imaging in HPV-related Oropharyngeal Cancer. W. SU, B.A. MILES, M. POSNER, P. SOM, L. KOSTAKOGLU, V. GUPTA, R.L. BAKST (New York, NY, USA) ........................................................................ 1525

Synthesis and Binding of a Novel PSMA-specific Conjugate. A.R. HOLMBERG, M. MARQUEZ, L. LENNARTSSON, L. MEURLING, S. NILSSON (Stockholm, Sweden) .................................................................................................................. 1531

Characterization and Management of Borderline Ovarian Tumors – Results of a Retrospective, Single-center Study of Patients Treated at the Department of Gynecology and Obstetrics of the University Medicine Greifswald. D. KOENSGEN, M. WEISS, K. ASSMANN, S.Y. BRUCKER, D. WALLWIENER, M.B. STOPE, A. MUSTEA (Greifswald; Tuebingen, Germany) ..................................................................................................... 1539

Functionality of the Tumor Suppressor microRNA-1 in Malignant Tissue and Cell Line Cells of Uterine Leiomyosarcoma. M.B. STOPE, V. CERNAT, A. KAUL, K. DIESING, D. KOENSGEN, M. BURCHARDT, A. MUSTEA (Greifswald, Germany) ........................................................................................................ 1547


Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer. Y. KOI, C. KOGA, S. AKIYOSHI, T. MASUDA, H. IIJICII, Y. NAKAMURA, M. ISHIDA, S. OHNO, E. TOKUNAGA (Hiroshima; Fukuoka; Tokyo, Japan) ........................................................................................................ 1579

Contents continued on the preceding page
Suppressive Effect of Delta-Tocotrienol on Hypoxia Adaptation of Prostate Cancer Stem-like Cells. S. KANEKO, C. SATO, N. SHIOZAWA, A. SATO, H. SATO, N. VIRGONA, T. YANO (Gunma; Chiba, Japan) .... 1391

Reduced Tumour Proportion Scores for Programmed Cell Death Ligand 1 in Stored Paraffin Tissue Sections. Y. SATO, D. FUJIMOTO, K. UEHARA, H. KAWACHI, K. NAGATA, A. NAKAGAWA, K. OTSUKA, I. SAKANOUE, H. HAMAKAWA, Y. TAKAHASHI, Y. IMAI, K. TOMII (Kobe, Japan) ................................................................. 1401

Vitamins C and K3: A Powerful Redox System for Sensitizing Leukemia Lymphocytes to Everolimus and Barasertib. D. IVANOVA, Z. ZHELEV, D. LAZAROVA, P. GETSOV, R. BAKALOVA, I. AOKI (Stara Zagora; Sofia, Bulgaria; Chiba, Japan) ........................................ 1407

The Comparison Between Molecular Tumour Profiling in Microdissected and Surgical Tissue Samples. I. LACZMANSKA, M. SASIADEK, L. LACZMANSKI (Wroclaw, Poland) ........................................................................................................ 1415

Clinicopathological and Prognostic Significance of Epithelial Gremlin1 Expression in Gastric Cancer. R. HONMA, N. SAKAMOTO, A. ISHIKAWA, D. TANIYAMA, F. FUKADA, T. HATTORI, K. SENTANI, N. OUE, K. TANABE, H. OHDAN, W. YASUI (Hiroshima, Japan) ........................................................................................................ 1419

Pre-exposure to Fluorouracil Increased Trifluridine Incorporation and Enhanced its Anti-tumor Effect for Colorectal Cancer. T. BABA, T. KOKURYO, J. YAMAGUCHI, Y. YOKOYAMA, K. UEHARA, T. EBATA, M. NAGINO (Nagoya, Japan) ........................................................................................................ 1427


Polymorphisms of ABCB1, CYP3A4 and CYP3A5 Genes in Ovarian Cancer and Treatment Response in Poles. Ł. FISZER-MALISZEWSKA, Ł. ŁACZMAŃSKI, A. DOLIŃSKA, M. JAGAS, E. KOŁODZIEJSKA, M. JANKOWSKA, P. KUSNIERCZYK (Wroclaw, Poland) ........................................................................................................................................ 1455


Clinical Studies

Combined Oocyte Retrieval and Robot-assisted Hysterectomy in a Super Morbidly Obese Patient with Endometrial Carcinoma. E.H. CHUNG, P.C. BRADY, K.K. SMITH, M.R. DAVIS, M.G. MUTO, R.K. ASHBY, E.S. GINSBURG (Boston, MA, USA) ........................................................................................................ 1467

A Panel of Biomarkers for Diagnosis of Prostate Cancer Using Urine Samples. J. GUO, J. YANG, X. ZHANG, X. FENG, H. ZHANG, L. CHEN, H. JOHNSON, J.L. PERSSON, K. XIAO (Shenzhen; Beijing; Guangzhou, PR China; Sunnyvale, CA, USA; Malmö; Umeå, Sweden) ........................................................................................................ 1471


Experimental Studies

Detection of Distinct Changes in Gene-expression Profiles in Specimens of Tumors and Transition Zones of Tenascin-positive/-negative Head and Neck Squamous Cell Carcinoma. V. ZIVICOVA, P. GAL, A. MIFKOVA, S. NOVAK, H. KALTNER, M. KOLAR, H. STRNAD, J. SACHOVA, M. HRADILIOVA, M. CHOVANEC, H.-J. GABIUS, K. SMETANA JR, Z. FIK (Prague; Vestec, Czech Republic; Kosice, Slovak Republic; Munich, Germany) ........................................................................................................................................ 1279

Modulation of Tumor Cell Metabolism by Laser Photochemotherapy with Cisplatin or Zoledronic Acid In Vitro. P.G.B. HEYMANN, K.S.E. HENKENIUS, T. ZIEBART, A. BRAUN, K. HIRTHAMMER, F. HALLING, A. NEFF, R. MANDIC (Marburg; Fulda, Germany) ..................................................................................................................... 1291

Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells. G.-H. HA, D.-Y. KIM, E.-K. BREUER, C.K. KIM (Suwon, Republic of Korea; Maywood, IL, USA) .............................................................................................................................................. 1303

Chemotherapeutic Effect of CD147 Antibody-labeled Micelles Encapsulating Doxorubicin Conjugate Targeting CD147-Expressing Carcinoma Cells. T. ASAKURA, M. YOKOYAMA, K. SHIRAISHI, K. AOKI, K. OHKAWA (Tokyo, Japan) ............................................................................................................................................................ 1311

Mutational and Functional Analysis of FANCB as a Candidate Gene for Sporadic Head and Neck Squamous Cell Carcinomas. M.F. GLAAS, C. WIEK, L.-M. WOLTER, K. ROELLECKE, V. BALZ, V. OKPANYI, M. WAGENMANN, T.K. HOFFMANN, R. GRÄSSLIN, C. PLETENBERG, J. SCHIPPER, H. HANENBERG, K. SCHECKENBACH (Duesseldorf; Ulm; Essen, Germany) .............................................................................................................. 1317

Glucans and Cancer: Comparison of Commercially Available β-glucans – Part IV. V. VETVICKA, J. VETVICKOVA (Louisville, KY, USA) ............................................................................................................................................................... 1327

BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma. L. WALTER, L. HEINZERLING (Erlangen, Germany) .......................................................................................................................... 1335


Expression of Sphingosine Kinase-1 Is Associated with Invasiveness and Poor Prognosis of Oral Squamous Cell Carcinoma. K. KATO, M. SHIMASAKI, T. KATO, N. SEGAMI, Y. UEDA (Ishikawa, Japan) .............. 1361

Impact of Methadone on Cisplatin Treatment of Bladder Cancer Cells. M. MICHALSKA, S. SCHULTZSEEEMANN, I. KUCKUCK, A. KATZENWADEL, P. WOLF (Freiburg, Germany) ...................................................................................................................... 1369

Galangin Induces p53-independent S-phase Arrest and Apoptosis in Human Nasopharyngeal Carcinoma Cells Through Inhibiting P3K-AKT Signaling Pathway. C.-C. LEE, M.-L. LIN, M. MENG, S.-S. CHEN (Taichung, Taiwan, ROC) .......................................................................................................................................................... 1377

Contents continued on the preceding page